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Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI
disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and
immunodeficiency) are combined immunodeficiencies resulting from gain-of-function
mutations in the genes (PIK3CD and PIK3R1) encoding the subunits of phosphoinositide
3-kinase δ (PI3Kδ) and were first described in 2013. These mutations result in the
hyperactivation of the PI3K/AKT/mTOR/S6K signally pathways. In this mini-review we
have detailed the current treatment options for APDS. These treatments including
conventional immunodeficiency therapies such as immunoglobulin replacement,
antibiotic prophylaxis, and hematopoietic stem cell transplant. We also discuss the more
targeted therapies of mTOR inhibition with sirolimus and selective PI3Kδ inhibitors.
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Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease
(p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency)
is a combined immunodeficiency resulting from dominant, gain-of-function mutations in
the genes encoding p110δ (PIK3CD) and p85α (PIK3R1), the catalytic and regulatory subunits
of phosphoinositide 3-kinase δ (PI3Kδ). These mutations result in the hyperactivation of the
PI3K/AKT/mTOR/S6K signally pathways in immune cells (1–3).
Patients with APDS may develop immunodeficient and immunodysregulatory features
including recurrent respiratory tract infections, bronchiectasis, herpesvirus infections,
autoimmunity, non-neoplastic lymphoproliferation, and lymphoma, as well as neurodevelopment
delay and growth retardation (4, 5). Clinical cohort studies show that the manifestations of
APDS are highly variable, even within families carrying the same mutation, ranging from
asymptomatic adult patients to those with primary antibody deficiency, those with a profound
immunodeficiency causing early death, to others suffering from lymphoproliferation and
malignancy. Thus, the treatment of patients with APDS has varied considerably from simple
observation to haematopoietic stem cell transplant (HSCT) in childhood (4, 5). These studies
also suggest that disease manifestations mostly have a pediatric onset with recurrent respiratory
infections usually the first manifestation occurring in infancy or childhood [0–10 years of age in
(4, 5)] followed by bronchiectasis and autoimmunity in later childhood (4–6).
APDS due to gain-of-function mutations in the genes encoding p110δ (PIK3CD) and p85α
(PIK3R1) are termed APDS1 and APDS2 respectively. Previously we have described a cohort of
53 patients with APDS1, 50 of whom had the E1021K mutation and 3 of with the E525 mutation
(4). Similarly, Elkaim et al. (5) studied a cohort of 36 patients with APDS2 due to mutations within
splice acceptor and donor sites in exon 11 of PI3KR1. Comparing the clinical features of these
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APDS1 and APDS2 cohorts suggests a similar phenotype with
the exception that the APDS1 cohort had a higher prevalence of
bronchiectasis (60 vs. 18%) and lower prevalence of lymphoma
(13 vs. 25%) compared to APDS2, growth retardation was only
reported in the APDS2 cohort and there was an asymptomatic
E1021K mutation carrier in the APDS1 cohort compared no
asymptomatic individuals in the APDS2 cohort. To date there
has been no evidence that the different PIK3CD and PIK3R1
genesmutations lead to different APDS1 and APDS2 phenotypes,
however this does require further study. Also, there has been
no suggestion to date that APDS1 and APDS2 should be treated
differently.
Although APDS was only first described in 2013, many
individuals were already under the care of immunology services
with diagnoses such as common variable Immunodeficiency
(CVID) or combined immunodeficiency (CID), and being
treated with conventional therapies including prophylactic
antibiotics, immunoglobulin replacement, and in some
cases HSCT (1, 3). As patients with APDS can also
develop autoimmune and inflammatory complications,
others were on various immunosuppressive therapies. Our
increasing understanding of the underlying mechanism
of APDS however suggests a role for more targeted
treatment in this disorder such as direct inhibition of
the activated PI3Kδ by selective PI3Kδ inhibitors or
inhibition of the downstream mTOR pathway by Sirolimus
(3, 7).
In this mini-review will we review how APDS is treated,
examining the experience of using conventional immune
deficiency therapies in APDS including HSCT, and the more
recent experience of selective PI3Kδ inhibitors and Sirolimus.
These treatment options are summarized in Table 1.
CONVENTIONAL PID TREATMENTS IN
APDS
Individuals with APDS often have demonstrable antibody
deficiency and lymphopenia and recurrent infections. These
complications have led immunologists to treat APDS with
standard supportive therapies such as prophylactic antibiotic
therapy, immunoglobulin replacement therapy (IRT), andHSCT.
(4) and (5) revealed the frequency of conventional treatments in
patients with APDS.
ANTIMICROBIAL PROPHYLAXIS
In our APDS1 cohort 62% of patients currently received and 9%
had previously received antibiotic prophylaxis. Similarly, Elkaim
et al. (5) found 61% of patients with APDS2 were on antibiotic
prophylaxis. The antibiotic prophylactic regimens used were
similar to those used in patients with antibody defects, largely
Trimethoprim/Sulfamethoxazole or Azithromycin. Antibiotic
prophylaxis alone sufficed for some patients, however most
needed IRT (4, 5). Combined IRT and antibiotic prophylaxis
is especially important for patients with respiratory tract
infections in the context of established bronchiectasis (4,
5).
Although APDS is also associated with persistent, severe, or
recurrent herpesvirus infections (3, 4), in our cohort of patients
with APDS1 only 6% were on long term Acyclovir/Valaciclovir
due to previous herpes infections despite 49% of patients having
had a significant herpes infection previously. 13% of the patients
in our APDS1 cohort received antifungal prophylaxis due to
previous mucocutaneous candidiasis. No cases of Aspergillus
species infection in APDS have been reported.
In individuals with APDS who have received Mycobacterium
bovis bacillus Calmette Guèrin (BCG) vaccination, persistent
local BCG site skin reactions have been reported (4, 5).
Chiriaco et al. (8) reported that APDS patient monocytes-derived
macrophages failed to eliminate BCG infection in vitro, raising
the question as to whether APDS patients should be given
anti BCG therapy. However, disseminated BCGosis and other
mycobacterial infections have not been reported in APDS, and
so whilst individual patients have been treated for local BCG
infections, APDS patients are not routinely placed on anti-
mycobacterial prophylaxis.
IMMUNOGLOBULIN REPLACEMENT
THERAPY
Many patients with APDS have antibody deficiency and
associated recurrent respiratory tract infections. These antibody
defects range from poor vaccine responses and IgG subclass
deficiencies to significantly reduced IgG and IgA with normal
or elevated IgM. Many patients with APDS have a historical
diagnosis of specific antibody deficiency, subclass deficiency,
common variable immune deficiency and hyper IgM syndrome
and have been treated with IRT.
The majority of APDS patients, 87% in the Coulter et al.
(4) APDS1 cohort, and 89% in the Elkaim et al. (5) APDS2
cohort received long-term IRT with a reduction in bacterial
infection burden in most cases. IRT was administered as in
other antibody deficiencies, i.e., as a long-term therapy, given
as intravenous (IVIG) or subcutaneous (SCIG) infusions. IRT
is usually commenced at a dose of 0.4 g/kg/month in antibody
deficient patients without bronchiectasis and at a higher dose of
0.6 g/kg/month in patients with bronchiectasis (9–11).
IRT is of reported benefit in many patients with APDS
reducing respiratory tract infections (4, 12, 13). However, IRT
does not appear to prevent the development of the herpes
infections nor lymphoproliferative, autoimmune/inflammatory
complications nor lymphoma (4, 12, 14, 15). Furthermore,
in some APDS patients bronchiectasis has progressed despite
optimal IRT (4, 5, 12, 15).
Many patients with APDS develop recurrent respiratory
tract infections which often progress rapidly to bronchiectasis
in childhood (4, 5). Individuals with APDS and bronchiectasis
should be treated as in other patients with bronchiectasis,
including airway clearance, physiotherapy, influenza
immunization, patient education antibiotic treatment for
infective exacerbations, the consideration of interval intensive
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TABLE 1 | Treatment options in Activated PI3Kδ Syndrome (APDS).
Treatment Benefit in APDS Proposed mechanism of action in APDS
Antimicrobial prophylaxis (e.g.,
Trimethoprim/Sulfamethoxazole or Azithromycin)
Reduction in respiratory tract infections Prevention of respiratory bacterial infections
Immunoglobulin replacement therapy Reduction in respiratory tract infections Correction of antibody deficiency secondary to APDS
Haematopoietic stem cell transplantation Reduction in respiratory & herpes infections
Reduction in lymphoproliferation & autoimmunity
Replacement leukocytes effected by PI3Kδ
hyperactivation
Sirolimus (Rapmycin) Reduction in lymphoproliferation Reduction in mTOR hyperactivation
Selective PI3Kδ inhibitors (e.g., Leniolisib) Reduction in lymphoproliferation Reduction in PI3Kδ hyperactivation
physiotherapy and antibiotics, nebulized hypertonic saline
and bronchodilators, and prophylactic antibiotics where
these therapies may benefit. It is recommended that the
management and monitoring of patients with bronchiectasis and
immune deficiency should be provided through a joint clinical
immunology and respiratory (±pediatricians) care model
with access to specialist respiratory nursing and physiotherapy
services with an expertise in bronchiectasis (16–18).
HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
APDS can present as or evolve into a profound combined
immunodeficiency which leads into significant morbidity and
early death. Allogenic haematopoietic stem cell transplantation
(HSCT) has been performed to treat life-threatening infections
and as part of treatment for lymphoma (4, 5, 19). Nademi
et al. (19) reported a series of eleven patients with APDS
and severe immune deficiency who underwent HSCT in seven
pediatric centers. The diagnosis of APDS was made prior to
HSCT in five patients and retrospectively in six. Ten of the
11 bore the E102IK PIK3CD mutation, and one a PIK3R1
mutation. All had suffered severe sinopulmonary infection, four
had bronchiectasis, six severe Herpes family virus infection, four
enteropathy/colitis, eight lymphoproliferation, one intestinal
obstruction, three significant progressive liver disease due to
Cryptosporidium infection, one had glomerulonephritis and
one glomerulosclerosis. Five had received steroids ± Sirolimus
and seven immunoglobulin, and all were deteriorating despite
their treatment. Age at transplant ranged from 5 to 23 years.
Peripheral blood stem cells were used in 7 of the 11, five
were transplanted from a matched unrelated donor, four
from a matched sibling and two from a mismatched donor.
Various conditioning regimes were used, mostly Fludarabine
with either Treosulphan or Melphalan, and all but two were
given serotherapy. Two patients died from CMV/Adenovirus
pneumonitis and idiopathic pneumonitis respectively. Mild
(Grade I or II) Graft vs. Host Disease occurred in nine
patients, but fully resolved in all. Two patients had autoimmune
haemolytic anemia, and one encephalitis, these complications
also fully resolving. Eight of the nine surviving patients are off
IVIG and well, one has got low donor chimerism and is awaiting
a second HSCT (19). These preliminary data show that HSCT
can be curative with resolution of pre HSCT signs and symptoms,
and survival looks to be similar to that seen after HSCT for other
PIDs. Indeed, considering the considerable pre HSCT morbidity
in this cohort, less success might have been expected, and so it
seems a promising option for patients with progressive disease
unresponsive to other treatment. To date, long term sequelae do
not seem to be a problem with follow up between 8 months and
16 years. However, the risks and benefits of HSCT in patients with
severe lung disease are not clear, and longer term follow up in a
larger cohort is needed to ascertain the place of HSCT in treating
APDS.
IMMUNOSUPPRESSION
Thirty-four percent of our APDS1 cohort had autoimmune or
inflammatory disease with 30% of the cohort treated with at
least one course of immunosuppressive therapy. Cytopenias were
the most common autoimmune disease in APDS, but conditions
described include renal disease, inflammatory colitis, exocrine
pancreatic insufficiency, seronegative arthritis, cirrhosis, and
sclerosing cholangitis. In some cases renal or liver transplantation
was necessary (4, 5).
The autoimmune cytopenias have been found to be responsive
to steroids, rituximab and splenectomy (4, 12). Rituximab
therapy has been noted to be complicated by sustained B-cell
lymphopenia (4). Elgizouli et al. (12) described good clinical
response from prednisolone and maintenance mesalazine in
inflammatory bowel disease in APDS1. Hartman et al. (20)
described two patients with APDS and primary sclerosing
cholangitis who underwent liver transplantation. In one case the
cholangitis relapsed 3 years after the original transplant, and the
patient was awaiting re-transplantation.
Non-neoplastic lymphoproliferation including
lymphadenopathy, splenomegaly, hepatomegaly with lymphoid
aggregates in the respiratory and gastroenteric tract being a
very frequent finding in APDS. We found Rituximab to be
of some benefit in the management of these non-neoplastic
lymphoproliferation in five patients with APDS1 (4).
SIROLIMUS
The mTOR inhibitor, Sirolimus (Rapamycin) has been found
to decrease in non-neoplastic lymphoproliferation (3–5, 21,
22). mTOR (mammalian target of rapamycin) is activated
downstream of PI3K and has a prominent role in T cell
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metabolism and the regulation of immune responses (2, 3).
Previously Sirolimus therapy had been reported in a case of
APDS to reduce hepatosplenomegaly and lymphadenopathy,
increase naïve T cell frequencies, and restore T cell proliferation
and IL-2 secretion (3). Recently Maccari et al. (6) published
the initial findings of the ESID APDS registry. They looked
specifically at the use of Sirolimus/Rapamycin in APDS and
noted a significant benefit in the treatment of non-neoplastic
lymphoproliferative disease with 8/25 having complete response
and 11/25 having partial response to sirolimus. Sirolimus was
found to be of less benefit in treating APDS related-cytopenias
and gastrointestinal disease with complete response in 3/14 and
3/15 cases and a partial response in 2/14 and 3/15 of cases
respectively. Thus, studies to date support the use of Sirolimus
in treating APDS-related non-neoplastic lymphoproliferation,
though some patients may only develop partial benefit and
lymphoproliferation may reoccur after treatment cession. The
long-term benefits and risks of Sirolimus therapy remain to be
determined.
SELECTIVE PI3Kδ INHIBITORS
Selective PI3Kδ inhibitors have the potential to offer a targeted
treatment option for APDS patients with greater efficacy and
fewer side effects. PI3K inhibitor therapies have been tested
in oncology trials, resulting in the approval of Idelalisib, for
treatment of chronic lymphocytic leukemia and non-Hodgkin
lymphoma (23, 24). However, Idelalisib has a considerable side-
effect profile, including pneumonitis, transaminitis, and colitis
(24).
Leniolisib (CDZ173), is a potent oral inhibitor of the
p110δ subunit of PI3Kδ which is currently being studied
for the treatment of APDS by Novartis (NCT02435173) (7,
25). Rao et al. (7) described a 12-week, open label, multisite
clinical trial involving six individuals with APDS, all with
lymphadenopathy and splenomegaly on CT/MRI at baseline.
After an initial screening period of up to 50 days, including
an immunosuppressive/immunomodulatory treatment wash-out
period, all patients received Leniolisib in escalating doses (10,
30, 70mg BD for 4 weeks each receiving 12 weeks total). After
the 12 weeks of Leniolisib treatment, significant reduction in
lymph node sizes (mean 40%, 13–65%) and spleen volume (mean
39%, range 26–57%) was seen in all patients. Patients reported
an increase in wellbeing (Patient global assessment questionnaire
11 ± 11mm), decrease in fatigue and less disease activity,
as assessed by the physician global assessment questionnaire.
There was also an improvement in immunological markers
with a normalization of transitional B cell and naive B cell
populations, and reduction of senescent (CD57+ CD4-) T
cells, PD-1+CD4+ T cells, IgM levels and the cytokines and
chemokines TNF, IFNγ, CXCL13 & CXCL10. Five of six patients
proceeded to enroll in the open-label long term extension study
using Leniolisib 70mg BD. The sixth patient reportedly did not
enroll due to logistical reasons related to traveling. Rao et al.
(7) reported that during the first 9 months of this extension
study no patient has experienced significant adverse effects. This
initial report supports that Leniolisib, like Sirolimus, may be
a treatment for APDS-related lymphoproliferation. However,
the improvements in patient well-being and immunological
parameters also suggests Leniolisib and other PI3Kδ inhibitors
could have wider benefits for individuals with APDS, athough
further studies are required, particularly with regard to the effect
on respiratory complications of APDS.
The inhaled PI3Kδ inhibitor, GSK2269557 or Nemiralisib,
is also currently being studied in APDS sponsored by
GlaxoSmithKline (NCT02593539) (24, 26). Though an oral
inhibitor maybe more effective for lymphoproliferation; it is
proposed an inhaled inhibitor could benefit patients primarily
affected by airway infection and bronchiectasis. The GSK2269557
clinical trial has not as yet reported results, but is described
as a “multi-center, non-randomized, open-label, uncontrolled,
single group study to investigate the safety and pharmacokinetics
during 84 days repeat dosing treatment with 1,000 micrograms
of inhaled in addition to standard of care, in subjects with
APDS.” GSK2269557 is also currently being investigated as an
anti-inflammatory treatment in Chronic Obstructive Pulmonary
Disease (COPD) (26).
CONCLUSION
The great clinical heterogeneity of APDS means that treatment
needs to be carefully tailored to each patient’s needs. Some
asymptomatic family members need no treatment at all; patients
with defective antibody production and recurrent infections
may need supportive treatment such as prophylactic antibiotic
and/or IRT. The decision as to which treatment needs to
be made on clinical grounds. Patients with recurrent chest
infection need very careful management in conjunction with
a respiratory specialist as the development of life limiting
and life threatening bronchiectasis is one of the major
causes of early death in APDS. Sirolimus can be a very
effective treatment for lymphoproliferative disease, but whether
these benefits are sustained long term remains to be seen.
Specific PI3Kδ inhibitor therapies appear very attractive and
useful in resolving lymphoproliferation but serious side effects
have been reported and the results from ongoing clinical
trials will hopefully enable us to titrate the best dose and
means of delivery as well as delineate long term risks and
benefits. Preliminary data suggests that for younger patients
in the process of developing life limiting and life threatening
complications of APDS, HSCT is curative, but it carries a 10–
20% mortality risk and it is unclear whether severe lung disease
is reversed. Only with more outcome data from these therapies
will the role of each of these treatment modalities become
clear.
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